BRCA2 and breast cancer: For BRCA2 heterozygotes, the HR per SD for the association between the ER-positive PRS313 and breast cancer was 1.31, 95% CI (1.26–1.36),24 compared with 1.15, 95% CI (1.07–1.24) for contralateral breast cancer in this study.